Literature DB >> 29046503

Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator K-877 (Pemafibrate) on Postprandial hyperlipidemia.

Yoshio Fujioka1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29046503      PMCID： PMC5827081          DOI： 10.5551/jat.ED088

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN： 1340-3478            Impact factor:   4.928


× No keyword cloud information.
  16 in total

1.  Effects of K-877, a novel selective PPARα modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice.

Authors:  Kenta Takei; Yoshimi Nakagawa; Yunong Wang; Song-Iee Han; Aoi Satoh; Motohiro Sekiya; Takashi Matsuzaka; Hitoshi Shimano
Journal:  J Pharmacol Sci       Date:  2017-02-11       Impact factor: 3.337

2.  Impact of Total Risk Management on Coronary Plaque Regression in Diabetic Patients with Acute Coronary Syndrome.

Authors:  Ryo Naito; Katsumi Miyauchi; Hiroyuki Daida; Takeshi Morimoto; Takafumi Hiro; Takeshi Kimura; Yoshihisa Nakagawa; Masakazu Yamagishi; Yukio Ozaki; Masunori Matsuzaki
Journal:  J Atheroscler Thromb       Date:  2016-03-08       Impact factor: 4.928

3.  Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.

Authors:  Marshall B Elam; Henry N Ginsberg; Laura C Lovato; Marshall Corson; Joseph Largay; Lawrence A Leiter; Carlos Lopez; Patrick J O'Connor; Mary Ellen Sweeney; Daniel Weiss; William T Friedewald; John B Buse; Hertzel C Gerstein; Jeffrey Probstfield; Richard Grimm; Faramarz Ismail-Beigi; David C Goff; Jerome L Fleg; Yves Rosenberg; Robert P Byington
Journal:  JAMA Cardiol       Date:  2017-04-01       Impact factor: 14.676

4.  Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia.

Authors:  Hidenori Arai; Shizuya Yamashita; Koutaro Yokote; Eiichi Araki; Hideki Suganami; Shun Ishibashi
Journal:  Atherosclerosis       Date:  2017-03-24       Impact factor: 5.162

Review 5.  Remnant lipoproteins as strong key particles to atherogenesis.

Authors:  Yoshio Fujioka; Yuichi Ishikawa
Journal:  J Atheroscler Thromb       Date:  2009-06-25       Impact factor: 4.928

Review 6.  Fibrates for primary prevention of cardiovascular disease events.

Authors:  Tobias Jakob; Alain J Nordmann; Stefan Schandelmaier; Ignacio Ferreira-González; Matthias Briel
Journal:  Cochrane Database Syst Rev       Date:  2016-11-16

7.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.

Authors:  C Baigent; L Blackwell; J Emberson; L E Holland; C Reith; N Bhala; R Peto; E H Barnes; A Keech; J Simes; R Collins
Journal:  Lancet       Date:  2010-11-08       Impact factor: 79.321

8.  A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice.

Authors:  Masami Sairyo; Takuya Kobayashi; Daisaku Masuda; Koutaro Kanno; Yinghong Zhu; Takeshi Okada; Masahiro Koseki; Tohru Ohama; Makoto Nishida; Yasushi Sakata; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2017-08-05       Impact factor: 4.928

9.  Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

Authors:  Russell Scott; Richard O'Brien; Greg Fulcher; Chris Pardy; Michael D'Emden; Dana Tse; Marja-Riitta Taskinen; Christian Ehnholm; Anthony Keech
Journal:  Diabetes Care       Date:  2008-11-04       Impact factor: 19.112

Review 10.  Postprandial Hyperlipidemia and Remnant Lipoproteins.

Authors:  Daisaku Masuda; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2016-11-08       Impact factor: 4.928
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.